C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 211/80 (2006.01) A61K 31/445 (2006.01)
Patent
CA 2630254
The invention is directed to the L-tartrate salt of trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-ethenyl-3-hydroxy-2,4,7, 14-tetramethyl-9- oxotricyclo[5.4.3.01,8]tetradec-6-yl imidodicarbonate (Compound IA.) Compound IA is useful for the treatment of a variety of diseases and conditions, such as respiratory tract and skin and skin structure infections. Accordingly, the invention is further directed to pharmaceutical compositions comprising Compound IA. The invention is still further directed to methods of treating respiratory tract and skin and skin structure infections using Compound IA or a pharmaceutical composition comprising Compound IA.
La présente invention concerne le sel L-tartrate du trans-3-aminocyclobutyl (lS,2R,3S,4S:,6R,7R,8R-,14R)-4-éthényl-3-hydroxy-2,4,7, 14-tétraméthyl-9-oxotricyclo[5.4.3.01,8]tétradec-6-yl imido dicarbonate (composé IA). Le composé IA est utilisable pour le traitement de maladies et d'états variés tels que des infections des voies respiratoires et de la peau et des structures cutanées. En conséquence, l'invention concerne en outre des compositions pharmaceutiques comprenant le composé IA. L'invention concerne de plus des procédés de traitement d'infections des voies respiratoires et de la peau et des structures cutanées à l'aide du composé IA ou d'une composition pharmaceutique comprenant le composé IA.
Igo David H.
Norton Beth A.
Glaxo Group Limited
Gowling Lafleur Henderson Llp
Igo David H.
Norton Beth A.
LandOfFree
New pleuromutilin derivative and its use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with New pleuromutilin derivative and its use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New pleuromutilin derivative and its use will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1489217